SOLID TUMOR PIPELINE
ProductMechanism

Indication

Phase 1

Phase 2Phase 3

Countries Where Registered

1L NonSq NSCLCEU and some ex-EU countries

1L Sq NSCLCEU and some ex-EU countries

2/3L NSCLCEU and some ex-EU countries

Neo/adj NSCLC

Tislelizumab

anti-PD-1

1L ES-SCLC

China

1L ESCC

China

2L ESCC

US, EU, and some ex-US, ex-EU countries

LA ESCC
1L GC/GEJC

China

1L NPCChina

1L HCCChina

1L UBC
China

2/3L HCC
1L NSCLC (subcutaneous formulation)

Ociperlimab

anti-TIGIT

BG-685011

CDK2 inhibitor

1L PD-L1 high NSCLCNSCLC dose confirmation
BC and solid tumors

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; 3L, third line; BC, breast cancer; CDK2, cyclin-dependent kinase 2; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; LA, locally advanced; NPC, nasopharyngeal carcinoma;
NonSq, non-squamous; NSCLC, non–small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; Sq, squamous; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; UBC, urothelial bladder cancer.
Ensem collaboration; BeiGene has global rights.

1

PAGE 1 of 3

FOR INFORMATION ON A PRODUCT REGISTRATION STATUS OR FOR DETAILS ON THE APPROVED USES IN YOUR COUNTRY, CONTACT A BEIGENE REPRESENTATIVE
OR MEDICALINFORMATION@BEIGENE.COM OR REFER TO APPROVED PRODUCT INFORMATION.

0120-BGB-A283-MRC-001

August 2024SOLID TUMOR PIPELINE
ProductMechanism

Indication

BGB-43395

CDK4 inhibitor

BC and solid tumors

BG-C90741

B7H4 ADC

BC and solid tumors

BGB-C354

B7H3 ADC

Solid tumors

LBL-0072

anti-LAG3

Phase 1

Phase 2Phase 3

Countries Where Registered

MSS-CRC
1L ESCC
1L NSCLCa

Umbrella

IO combinations

Neo/adj NSCLCa
2L+ NSCLCa
1L HNSCCa
2L HER2+ BTC

Zanidatamab3

anti-HER2 BsAb

BGB-A445

anti-OX40

Melanoma, UC

BGB-15025

HPK1 inhibitor

Solid tumors

BGB-26808

HPK1 inhibitor

Solid tumors

BGB-24714

SMAC mimetic

Solid tumors

1L HER2+ GEA

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; ADC, antibody-drug conjugate; BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; CDK4, cyclin-dependent kinase 4; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; GEA, gastroesophageal adenocarcinomas; HER2, human epidermal growth factor receptor 2; HNSCC, head andneck squamous cell carcinoma; HPK1, hematopoietic progenitor kinase 1; IO, immunotherapy; LAG3, lymphocyte activation gene 3; MSS, microsatellite stability; NSCLC, non–small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PD-1, programmed cell death protein 1; SMAC, second mitochondria-derived
activator of caspase; UC, urothelial carcinoma.
May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.
DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights.
2Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China.
3Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand.
a1

PAGE 2 of 3

FOR INFORMATION ON A PRODUCT REGISTRATION STATUS OR FOR DETAILS ON THE APPROVED USES IN YOUR COUNTRY, CONTACT A BEIGENE REPRESENTATIVE
OR MEDICALINFORMATION@BEIGENE.COM OR REFER TO APPROVED PRODUCT INFORMATION.

0120-BGB-A283-MRC-001

August 2024

SOLID TUMOR PIPELINE
ProductMechanism

Indication

BGB-30813

DGKζ inhibitor

Solid tumors

BGB-A3055

anti-CCR8

Solid tumors

Pamiparib

PARP 1/2 inhibitor

2L MTx gBRCAm PSOC

Phase 1

Phase 2Phase 3

Countries Where Registered

2L SCLC

Tarlatamab1

DLL3 x CD3

1L-ES-SCLC
LS-SCLC
3L+ SCLC (initiation activities)

Xaluritamig1

STEAP1 x CD3mCRPC

BGB-R046

IL-15 prodrug

Solid tumors

BGB-B3227

MUC1 x CD16A BsAb

Lung and GI

BGB-B2033

GPC3 x 4-1BB

Solid tumors

BG-C477

CEA ADC

Lung and GI cancers (preclinical)

Planned for 2024

BGB-53038

PanKRAS inhibitor

Lung and GI cancers (preclinical)

Planned for 2024

BG-C137

FGFR2b ADC

GI cancer (preclinical)

Planned for 2024

BGB-58067

PRMT5 inhibitor

Lung and GI cancers (preclinical)

Planned for 2024

BG-60366

EGFR-targeted CDAC

Lung cancer (preclinical)

Planned for 2024

Safety and efficacy have not been established for investigational products and/or uses.

Abbreviations: 1L, first line; 2L, second line; 3L, third line; 4-1BB, tumor necrosis factor receptor superfamily member 9; ADC, antibody-drug conjugate; BsAb, bispecific antibody; CCR8, the C-C motif chemokine receptor 8; CD16A, Fc receptor FcγRIIIa; CD3, cluster of differentiation 3; CDAC, chimeric degradation activating compound; CEA, carcinoembryonicantigen; DGKζ, diacylglycerol kinase ζ; DLL3, delta-like ligand 3; EGFR, epidermal growth factor receptor; ES-SCLC, extensive-stage small cell lung cancer; FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; gBRCAm, germline BReast CAncer gene (BRCA) mutation; GI, gastrointestinal; GPC3, glypican-3; IL-15, interleukin-15; KRAS, Kirsten rat sarcoma virus;
LS-SCLC, limited-stage small cell lung cancer; mCRPC, metastatic castration-resistant prostate cancer; MTx, maintenance treatment; MUC1, mucin 1; PARP 1/2, poly (ADP-ribose) polymerase 1 and 2; PRMT5, protein arginine methyltransferase 5; PSOC, platinum-sensitive ovarian cancer; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigenof the prostate 1.
Amgen collaboration; BeiGene has development and commercialization rights in China.

1PAGE 3 of 3

FOR INFORMATION ON A PRODUCT REGISTRATION STATUS OR FOR DETAILS ON THE APPROVED USES IN YOUR COUNTRY, CONTACT A BEIGENE REPRESENTATIVEOR MEDICALINFORMATION@BEIGENE.COM OR REFER TO APPROVED PRODUCT INFORMATION.

0120-BGB-A283-MRC-001

August 2024